Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer

A. U. Buzdar, J. U. Gutterman, G. R. Blumenschein, G. N. Hortobagyi, C. K. Tashima, T. L. Smith, Evan M Hersh, E. J. Freireich, E. A. Gehan

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

For the past 34 months, a combination of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC-BCG, the estimated proportion remaining disease-free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p<.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2-year survival rates were 96% for FAC-BCG patients and 86% for control (p= .02). Treatment was well tolerated. Adjuvant FAC-BCG seems effective in prolonging disease-free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow-ups.

Original languageEnglish (US)
Pages (from-to)1064-1075
Number of pages12
JournalCancer
Volume41
Issue number3
DOIs
StatePublished - 1978
Externally publishedYes

Fingerprint

Breast Neoplasms
Mycobacterium bovis
Fluorouracil
Doxorubicin
Cyclophosphamide
Survival Rate
Survival
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Buzdar, A. U., Gutterman, J. U., Blumenschein, G. R., Hortobagyi, G. N., Tashima, C. K., Smith, T. L., ... Gehan, E. A. (1978). Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer, 41(3), 1064-1075. https://doi.org/10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q

Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. / Buzdar, A. U.; Gutterman, J. U.; Blumenschein, G. R.; Hortobagyi, G. N.; Tashima, C. K.; Smith, T. L.; Hersh, Evan M; Freireich, E. J.; Gehan, E. A.

In: Cancer, Vol. 41, No. 3, 1978, p. 1064-1075.

Research output: Contribution to journalArticle

Buzdar, AU, Gutterman, JU, Blumenschein, GR, Hortobagyi, GN, Tashima, CK, Smith, TL, Hersh, EM, Freireich, EJ & Gehan, EA 1978, 'Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer', Cancer, vol. 41, no. 3, pp. 1064-1075. https://doi.org/10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q
Buzdar, A. U. ; Gutterman, J. U. ; Blumenschein, G. R. ; Hortobagyi, G. N. ; Tashima, C. K. ; Smith, T. L. ; Hersh, Evan M ; Freireich, E. J. ; Gehan, E. A. / Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. In: Cancer. 1978 ; Vol. 41, No. 3. pp. 1064-1075.
@article{0b3c242487bd429bb48a47e45e195cb1,
title = "Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer",
abstract = "For the past 34 months, a combination of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC-BCG, the estimated proportion remaining disease-free at 2 years from surgery was 91{\%} compared to an estimated 69{\%} in a group of 151 historical control patients (p<.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2-year survival rates were 96{\%} for FAC-BCG patients and 86{\%} for control (p= .02). Treatment was well tolerated. Adjuvant FAC-BCG seems effective in prolonging disease-free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow-ups.",
author = "Buzdar, {A. U.} and Gutterman, {J. U.} and Blumenschein, {G. R.} and Hortobagyi, {G. N.} and Tashima, {C. K.} and Smith, {T. L.} and Hersh, {Evan M} and Freireich, {E. J.} and Gehan, {E. A.}",
year = "1978",
doi = "10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q",
language = "English (US)",
volume = "41",
pages = "1064--1075",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer

AU - Buzdar, A. U.

AU - Gutterman, J. U.

AU - Blumenschein, G. R.

AU - Hortobagyi, G. N.

AU - Tashima, C. K.

AU - Smith, T. L.

AU - Hersh, Evan M

AU - Freireich, E. J.

AU - Gehan, E. A.

PY - 1978

Y1 - 1978

N2 - For the past 34 months, a combination of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC-BCG, the estimated proportion remaining disease-free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p<.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2-year survival rates were 96% for FAC-BCG patients and 86% for control (p= .02). Treatment was well tolerated. Adjuvant FAC-BCG seems effective in prolonging disease-free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow-ups.

AB - For the past 34 months, a combination of 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC-BCG, the estimated proportion remaining disease-free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p<.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2-year survival rates were 96% for FAC-BCG patients and 86% for control (p= .02). Treatment was well tolerated. Adjuvant FAC-BCG seems effective in prolonging disease-free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow-ups.

UR - http://www.scopus.com/inward/record.url?scp=0018178240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018178240&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q

DO - 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q

M3 - Article

VL - 41

SP - 1064

EP - 1075

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -